Beijing Protocol in Patients Receiving More Than 5/10 HLA-mismatched Allo-HSCT
The Safety and Efficiency of Beijing Protocol in Malignant Hematologic Disease Patients Receiving More Than 5/10 HLA-mismatched Allo-HSCT
Peking University People's Hospital
20 participants
Jun 1, 2023
OBSERVATIONAL
Conditions
Summary
The aim of the study is to evaluate the efficacy and safety of Beijing protocol in malignant haematologic disease patients receiving more than 5/10 HLA-mismatched allo-HSCT.
Eligibility
Inclusion Criteria4
- hematologic malignancy patients
- patients eligible for the transplantation of allogeneic hematopoietic stem cells;
- patients unavailable with HLA matched donor or related haploidentical donor
- voluntary participation in this study and signing the informed consent form.
Exclusion Criteria6
- Patients with the severe infections;
- Pregnant or lactating women
- Patients who are not eligible for hematopoietic stem cell transplantation;
- Patients who are enrolled in other clinical trials within 1 month;
- Patients who may not be able to complete the study for other reasons, or may be considered by the investigator not suitable to participate in the study;
- Patients unable to properly understand or refusing to accept the informed consent form.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
For patients \<55 years and HCT-CI≤ 3：Ara-C(4g/m2/day,-9 days),Bu(9.6mg/kg,-8 days to -6 days),Cy(1,800mg/m2/day,-5 days to -4 days),semustine(250mg/m2,-3 days),ATG(7.5-10 mg/kg,-5 to -2 days) For patients ≥ 55 years or HCI-CI\>3：Ara-C(2g/m2/day,-10 days to -9 days),Bu(9.6mg/kg,-8 days to -6 days),Flu(30mg/m2/day,-6 days to -2 days),Cy(1,000mg/m2/day,-5 days to -4 days),semustine(250mg/m2,-3 days),ATG(7.5-10 mg/kg,-5 to -2 days).
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05921318